- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05791331
Atmungsmechanik zur Abgabe individualisierter exogener Tenside (REMEDIES)
Eine randomisierte kontrollierte Studie zur Oszillationsmechanik im Vergleich zu sauerstoffbasierten Kriterien für die Surfactant-Therapie
This study is an interventional, non-pharmacological, multicentric, randomized, controlled, superiority, non-profit study. Its primary objective is to evaluate if the administration of surfactant based on FOT assessment will allow a 5-day reduction in the duration of respiratory support as compared to standard practice in preterm infants between 27+0 and 32+6 weeks' gestation. The secondary objectives are:
- to determine if a lung mechanics-based approach for administering surfactant will change treatment timing; and
- to assess the impact of the novel approach on other neonatal general outcomes. The study will take place within the neonatal intensive care units. Non-invasive respiratory support will be delivered by nasal CPAP with a starting pressure of 5-8 cmH2O. FiO2 will be titrated in order to achieve the target SpO2 91-95%.
Infants matching the clinical criteria for inclusion will be randomized in two arms following the current data protection and confidentiality regulations. Central, computer-generated randomization (allocation 1:1) with variable block sizes according to gestational age will be used. Infants will be stratified according to gestational age (27+0 -28+6 weeks; 29+0 -30+6 weeks; 31+0 -32+6 weeks) and center.
Study Arms:
A) Surfactant administration following oxygenation-based criteria (clinical assessment) (control) B) Surfactant administration following both lung mechanics assessment OR oxygenation-based criteria (clinical assessment) (intervention).
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Anna Lavizzari, MD
- Telefonnummer: 0039 3208715095
- E-Mail: anna.lavizzari@gmail.com
Studienorte
-
-
-
Milan, Italien
- Rekrutierung
- Fondazione IRCCs Cà Granda Ospedale Maggiore Policlinico
-
Kontakt:
- Anna Lavizzari, MD
- Telefonnummer: 0039 3208715095
- E-Mail: anna.lavizzari@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Gestational age (GA) ≥ 27+0 and < 33+0 weeks
- Spontaneously breathing infants, requiring non-invasive respiratory support (nasal CPAP or bilevel nasal CPAP). Criteria for commencement of non-invasive respiratory support: FiO2 >0.30 for target SpO2 88-93% or Silverman score ≥ 5.
- Inborn
- Written parental consent obtained
- Administration of Caffeine bolus 20 mg/kg IV or PO as per standard care
Exclusion Criteria:
- Major congenital anomalies
- Need of intubation in delivery suite according to the AAP guidelines for neonatal resuscitation or early at the admission in NICU (within one hour from birth).
- Surfactant therapy prior to the study entry
- Severe birth asphyxia, defined by APGAR score ≤ 5 at 10 minutes after birth OR continued need for resuscitation 10 minutes after birth OR pH < 7.0 or base excess (BE) < -12 mmol/l on umbilical cord or on an arterial or capillary blood sample obtained within 1 hour from birth OR moderate to severe encephalopathy
- Respiratory failure secondary to conditions other that RDS as identified by lung imaging (air leaks, lung malformations…)
- Any clinical condition which may place the infants at undue risk as deemed by clinicians
- Participation to trials with competitive outcomes or likely to have an impact on the primary outcome of the study
- Outborn patients
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: A/Control
Surfactant administration following clinical assessment |
Surfactant is administered following oxygenation-based criteria |
|
Experimental: B/Intervention
Surfactant administration following both lung mechanics assessment and clinical assessment |
Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O*s /L |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Days of respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of required respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
First surfactant administration
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Time of first surfactant administration (in hours) |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days of non-invasive respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of non-invasive respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days of invasive respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of invasive respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Patients intubated and mechanically ventilated
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of patients intubated and mechanically ventilated |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Patients receiving multiple surfactant doses
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of patients receiving multiple surfactant doses |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days on supplemental oxygen
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days on supplemental oxygen |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Total cumulative oxygen exposure
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Total cumulative oxygen exposure computed as the time integral of the FiO2 values |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants receiving more than 28 days of respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants receiving more than 28 days of respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants developing BPD
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants developing BPD according to the definition by NICHD 2016 |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants developing air-leaks
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants developing air-leaks |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants developing prematurity-associated complications
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants developing prematurity-associated complications (severe intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), sepsis, retinopathy of prematurity (ROP), patent ductus arteriosus requiring pharmacological or surgical treatment) |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants discharged home with oxygen or respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants discharged home with oxygen or respiratory support |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days to achieve full-enteral feeding
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days to achieve full-enteral feeding (160 ml/kg/day of milk intake) |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Days of hospitalization
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of days of hospitalization |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
|
Infants receiving postnatal steroids
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Number of infants receiving postnatal steroids |
From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
|
Mitarbeiter und Ermittler
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Sperimentazione 3115
- Studio Numero 6379 (Andere Kennung: Comitato Etico Milano Area 2)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .